BioSpace News Archive

Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the fourth quarter of 2019 on Thursday, February 6, 2020

FORMA Therapeutics, Inc., a clinical stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the closing of $100 million Series D financing

Exelixis, Inc. (NASDAQ:EXEL) today announced a collaboration agreement with Roche to evaluate cabozantinib (CABOMETYX®), Exelixis’ small molecule inhibitor of receptor tyrosine kinases, in combination with atezolizumab (TECENTRIQ®), Roche’s PD-L1 immune checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors.

Medasense Biometrics Ltd. has been awarded a development grant from the Israel Innovation Authority (IIA) to extend the application of its NOL® pain response monitoring index for noncommunicating dementia patients.

NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune Modulation (AIM) nanotechnology platform, has received IND clearance for the Company’s second cellular therapy product.

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, today announced the first patient dosed with AGEN1181, an anti-CTLA-4 antibody, in combination with balstilimab, Agenus’ PD-1 inhibitor.

TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced the company will present at the upcoming 38th Annual J.P. Morgan Healthcare Conference in San Francisco.

Catalyst to receive $15 million upfront and is eligible to receive an additional $340 million in milestones and tiered royalties up to low double digits

Salarius Pharmaceuticals, Inc. announced that its chief executive officer, David Arthur, will present at the Biotech Showcase 2020 conference being held January 13-15, 2020 at the Hilton San Francisco Union Square in San Francisco, California.

Plinabulin Protects Bone Marrow from Chemotherapy-Induced Deficiencies with a Differentiated Yet Complimentary Mechanism to G-CSF for CIN Prevention